Leukemia

Latest News


This week, we spoke with former NFL coach, motivational speaker and acute promyelocytic leukemia survivor Chuck Pagano about his journey with cancer, and what has inspired him to give back following his diagnosis.

The FDA has granted a priority designation to a supplemental new drug application (sNDA) for Imbruvica (ibrutinib) for use in combination with Gazyva (obinutuzumab) for the frontline treatment of adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

The Food and Drug Administration (FDA) approved the use of Lumoxiti (moxetumomab pasudotox-tdfk) for patients with relapsed or refractory hairy cell leukemia (HCL) who previously had at least two prior systemic therapies, including treatment with a purine nucleoside analog.

What is CLL?

By

Equipping with knowledge to improve patient-physician communication and understanding the disease.

Better treatment options have put chronic lymphocytic leukemia in the spotlight in recent years. But just what is CLL?